




Very-late onset Primary CNS Post-transplant Lymphoproliferative Disease (PTLD): report of three cases and literature review



Lapucci C¹, Massa F¹, Boffa G¹, Mancardi GL¹, Delucchi S², Barletta L³, Mikulska M⁴, Zona G⁵, Ravetti J⁶, Grandis M¹, Capello E¹, Benedetti L¹

PTLD is a heterogeneous disease, affecting patients following solid organ transplant (SOT). Although considered historically a rare disease (<2% in transplanted population), its importance is increasing over the last 2 decades, because of the spreading of SOT and immunosuppression-associated complications.

Isolated CNS involvement occur in 7-15%.


The distinctive characteristics compared to systemic PTLD are the **stronger association with renal SOT**, **later onset** and **monomorphic histology**.

Up to date, the biggest retrospective and multicenter report included 84 patients (median latency 4.5 years)

We report **three cases** whose key features are in line with published reports, but which can be considered **atypical due to the latency between SOT and CNS-PTLD**

Case 1


Female, 88-year-old
SOT: **kidney 10 years before**
Immunosuppressive therapy: **Mycophenolate Mofetil**
Clinical data and neurological examination: subacute-onset of cephalgia with temporal disorientation and gait disturbance
CSF: mild pleiocytosis, B oligoclonal pattern
Brain biopsy: **Monomorphic Diffuse Large B-cell CNS-PTLD**



multiple T2 hyperintense supratentorial lesions
necrosis, edema and mass effect


Case 2

Male, 67-year-old
SOT: **kidney 10 years before**
Immunosuppressive therapy: **Mycophenolate Mofetil** and **Tacrolimus**
Clinical data and neurological examination: sensitive partial seizure with secondary generalization
CSF: mild pleiocytosis, B oligoclonal pattern
Autopsy: **Monomorphic Diffuse Large B-cell CNS-PTLD**



Case 3

Female, 71-year-old
SOT: **kidney 20 years before**
Immunosuppressive therapy: **Mycophenolate Mofetil** and **Ciclosporin**
Clinical data and neurological examination: sudden onset of speech disturbances, progressively followed by poor orientation in time
CSF: single prevalent clone in oligoclonal B cells pattern, T policlonal pattern
Brain biopsy: **Monomorphic Diffuse Large B-cell CNS-PTLD**



In our cases, the **latency** between SOT and onset of neurological symptoms is **significantly higher** (median time **13.5 years**) than that described in literature (median time 4.5 years)

THE DIAGNOSIS OF THE VERY-LATE ONSET CNS-PTLD IS A REAL CHALLENGE

The less deducible relation with past transplantation and the age-related comorbidities can lead to a misdiagnosis and to a subsequent inappropriate therapeutic approach.

1 Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Italy
2 Department of Neuroradiology, S. Andrea Hospital, La Spezia, Italy
3 Department of Neuroradiology, S. Martino Hospital, Genoa, Italy
4 Department of Infectious Diseases, S. Martino Hospital, Genoa, Italy
5 Department of Neurosurgery, S. Martino Hospital, Genoa, Italy
6 Department of Pathological Anatomy, S. Martino Hospital, Genoa, Italy

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era, Evens et al., Am Jour of Transplantation 2013
Epstein-Barr virus encephalitis in a renal transplant recipient manifesting as hemorrhagic, ring-enhancing mass lesions, Babik et al., Transpl Infect Dis, 2015